Other intangible assets (Tables)

12 Months Ended

Mar. 31, 2026

Disclosure of detailed information about intangible assets [abstract]

Disclosure of detailed information about intangible assets explanatory [text block]

The following is a summary of changes in the carrying value of intangible assets:

	Product related intangibles			Customer related intangibles		Others			Total
Gross carrying value
Balance as of April 1, 2024	Rs.	124,013		Rs.	106	Rs.	6,667		Rs.	130,786
Additions (1)		9,081			-		908			9,989
Assets acquired through business combinations (2)		56,955			-		-			56,955
Disposals/De-recognitions		(380	)		-		(7	)		(387	)
Effect of changes in foreign exchange rates		3,013			3		-			3,016
Balance as of March 31, 2025	Rs.	192,682		Rs.	109	Rs.	7,568		Rs.	200,359

Balance as of April 1, 2025	Rs.	192,682		Rs.	109	Rs.	7,568		Rs.	200,359
Additions (1)		11,296			-		829			12,125
Assets acquired through business combinations (2)		-			-		-			-
Disposals/De-recognitions		(1,335	)		-		(178	)		(1,513	)
Effect of changes in foreign exchange rates		16,323			20		20			16,363
Balance as of March 31, 2026	Rs.	218,992		Rs.	129	Rs.	8,213		Rs.	227,334

Amortization/impairment loss
Balance as of April 1, 2024	Rs.	90,476		Rs.	106	Rs.	3,253		Rs.	93,835
Amortization for the year		6,146			-		407			6,553
Impairment loss, net (4)		1,689			-		-			1,689
Disposals/De-recognitions		(75	)		-		-			(75	)
Effect of changes in foreign exchange rates		1,544			3		7			1,554
Balance as of March 31, 2025	Rs.	99,780		Rs.	109	Rs.	3,667		Rs.	103,556

Balance as of April 1, 2025	Rs.	99,780		Rs.	109	Rs.	3,667		Rs.	103,556
Amortization for the year		7,448			-		537			7,985
Impairment loss, net (3)		2,164			-		-			2,164
Disposals/De-recognitions		(280	)		-		(22	)		(302	)
Effect of changes in foreign exchange rates		8,848			20		4			8,872
Balance as of March 31, 2026	Rs.	117,962		Rs.	129	Rs.	4,184		Rs.	122,275
Net carrying value
As of March 31, 2024	Rs.	33,537		Rs.	-	Rs.	3,414		Rs.	36,951
As of March 31, 2025	Rs.	92,902		Rs.	-	Rs.	3,901		Rs.	96,803
As of March 31, 2026	Rs.	101,030			-	Rs.	4,029		Rs.	105,059

(1)

Additions during the year ended March 31, 2026, primarily consists of:

Rs.4,464 (U.S.$50.50) paid as consideration for the acquisition of STUGERON® and its locally recognized brands covering 18 markets in the Asia-Pacific and Europe, Middle East, and Africa regions, with India and Vietnam as the key markets.

Rs.3,014 (U.S.$.32.15) paid as consideration to acquire the trademarks and related assets for Progynova® and Cyclo-Progynova® in India.

Rs.1,781 (U.S.$20) pertaining to the upfront consideration pursuant to the acquisition of exclusive commercialization rights to eftilagimod alfa from Immutep Limited (“Immutep”) in all the territories outside North America, Europe, Japan and Greater China. Of this amount, U.S.$10 was refundable if the futility analysis performed by Immutep provides an unsatisfactory outcome.

(Refer to Impairment recorded during the year ended March 31, 2026 for further details).

Additions during the year ended March 31, 2025, primarily consists of:

Rs.5,025 (U.S.$58) pertaining to the upfront consideration and other additional milestone consideration paid pursuant to the acquisition of exclusive rights to commercialize daratumumab biosimilar HLX 15 in the United States and Europe from Shanghai Henlius Biotech, Inc. (“Henlius”). Under the terms of the agreement, Henlius is responsible for development, manufacturing and commercial supply, and is eligible to receive consideration upon achievement of commercial milestones, bringing the total potential consideration (including upfront consideration and milestone payments) of up to Rs.11,243 (U.S.$131.6). In addition, Henlius is eligible to receive royalties on annual net sales of the product upon commercialization.

Rs.1,764 (U.S.$ 20.70) paid as upfront consideration and additional milestone consideration for the acquisition of exclusive rights in the United States, and semi-exclusive rights in Europe and the United Kingdom, to commercialize AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®.

The acquisition of the rights to commercialize Helinorm, a food supplement product, in Russia and other countries, for a consideration of Rs.820 (RUB 970).

(2)

Refer to Note 35 of these consolidated financial statements for details regarding assets acquired through business combinations during the year ended March 31, 2025.

Disclosure Of Detailed Information About Intangible Assets Under Development [Text Block]

Tabulated below is the reconciliation of amounts relating to in-process research and development assets as at the beginning and at the end of the year:

	As of March 31,
	2026			2025
Opening balance	Rs.	662		Rs.	683
Add: Additions during the year		-			85
Less: Capitalizations during the year		(267	)		(70	)
Less : Impairment (3)		(406	)		(43	)
Effect of changes in foreign exchange rates		11			7
Closing balance	Rs.	-		Rs.	662

Description of significant separately acquired Intangible Assets [text block]

Details of significant acquired intangible assets as of March 31, 2026 are as follows:

Particulars of the asset	Acquired from	Carrying net book value
Consumer Healthcare Portfolio of Nicotine Replacement Therapy	Haleon UK Enterprises Limited	Rs.	58,245
Select portfolio of branded generics business	Wockhardt Limited		10,022
daratamumab biosimilar HLX 15	Shanghai Henlius Biotechz,Inc		5,500
Antivertigo Brand Stugeron® in India	Janssen Pharmaceutica NV		4,350
Cardiovascular brand Cidmus ® in India	Novartis AG		4,005
Progynova® and Cyclo-Progynova® in India	Mercury Pharma Group Limited		3,014